| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
L-type calcium channels. It blocks calcium influx through L-type calcium channels, leading to vasodilation and negative inotropic and chronotropic effects.
|
|---|---|
| ln Vitro |
Norverapamil D7 has similar pharmacological activity to non-deuterated norverapamil. It exhibits calcium channel blocking activity with potency comparable to the parent metabolite. It inhibits L-type calcium channel-mediated calcium influx in vascular smooth muscle and cardiac cells.
|
| ln Vivo |
The deuterated compound is primarily used as an analytical reference standard. In vivo studies focus on pharmacokinetic characterization, including metabolic stability and half-life determination. Deuterium incorporation can prolong half-life by reducing metabolic clearance.
|
| Enzyme Assay |
Calcium channel binding assays use radiolabeled ligands such as 3H-nitrendipine or 3H-verapamil. Recombinant L-type calcium channels or cardiac membrane preparations are incubated with the radioligand and serially diluted test compound. Bound radioactivity is quantified, and Ki values are calculated from the dose-response curve.
|
| Cell Assay |
Functional assays for calcium channel activity use vascular smooth muscle cells or cardiomyocytes. Cells are loaded with a calcium-sensitive fluorescent dye (e.g., Fura-2), and calcium influx is stimulated with KCl or Bay K8644. The inhibitory effect of test compounds on calcium influx is measured by fluorescence, and IC50 values are calculated.
|
| Animal Protocol |
In vivo studies with Norverapamil D7 focus on pharmacokinetic characterization. Rats or dogs are administered the compound, and plasma concentrations are measured by LC-MS/MS. Parameters such as Cmax, Tmax, AUC, t1/2, and clearance are determined. The deuterium isotope effect on metabolic stability is evaluated.
|
| References |
|
| Molecular Formula |
C26H36N2O4
|
|---|---|
| Molecular Weight |
447.6182
|
| Exact Mass |
447.311
|
| CAS # |
263175-44-6
|
| Related CAS # |
Norverapamil;67018-85-3;Norverapamil-d7 hydrochloride;1216413-74-9
|
| PubChem CID |
45040133
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.3
|
| tPSA |
72.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
32
|
| Complexity |
577
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])(C([2H])([2H])[2H])C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
|
| InChi Key |
UPKQNCPKPOLASS-HXAWLNHQSA-N
|
| InChi Code |
InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/i1D3,2D3,19D
|
| Chemical Name |
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-(1,1,1,2,3,3,3-heptadeuteriopropan-2-yl)pentanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2340 mL | 11.1702 mL | 22.3404 mL | |
| 5 mM | 0.4468 mL | 2.2340 mL | 4.4681 mL | |
| 10 mM | 0.2234 mL | 1.1170 mL | 2.2340 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.